Guidance
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.
This guidance has been partially updated by NICE’s antimicrobial prescribing guideline on Clostridioides difficile.
November 2019: The US Food and Drug Administration has advised that stool donors for faecal microbiota transplantation should be screened with questions that specifically address risk factors for colonisation with multi-drug resistant organisms (MDROs), and individuals at higher risk of colonisation with MDROs should be excluded as donors. In addition, donor stool should be specifically tested for MDROs and not used if positive.
Guidance development process
How we develop NICE interventional procedures guidance
Coding and clinical classification codes for this guidance